Ignite Creation Date:
2024-05-06 @ 8:28 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06394518
Status:
COMPLETED
Last Update Posted:
2024-05-01
First Post:
2024-04-27
Brief Title:
Phase 1 Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants
Sponsor:
TenNor Therapeutics Inc
Organization:
TenNor Therapeutics Inc
Study Overview
Official Title:
A Phase 1 Single-Center Randomized Double-Blind Placebo-Controlled Dose-Escalation Clinical Trial to Evaluate the Safety Tolerability and Pharmacokinetics of Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase 1 single-center randomized double-blind placebo-controlled dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None